文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

比较丁丙诺啡与美沙酮减少甲基苯丙胺渴求的效果:一项随机临床试验

Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial.
PubMed 文献 · Trials · 2017-06-06

该随机临床试验将40名符合DSM-5甲基苯丙胺依赖及戒断标准、寻求治疗的男性患者随机分为两组,分别接受每日40mg美沙酮或8mg丁丙诺啡治疗17天。两组均能降低甲基苯丙胺戒断期间的渴求,丁丙诺啡组的渴求降低程度显著大于美沙酮组(P<0.05)。作者认为丁丙诺啡作为甲基苯丙胺戒断渴求的短期治疗具有疗效和安全性优势。

要点

  • 丁丙诺啡组渴求降低程度显著大于美沙酮组(P<0.05)。
  • 40名患者全部完成17天治疗,两组均降低甲基苯丙胺渴求。
  • 作者认为丁丙诺啡作为短期治疗具有疗效和安全性优势。

核心结论

  • 结果支持丁丙诺啡作为甲基苯丙胺戒断渴求短期治疗的疗效和安全性。
  • 作者指出渴求预期会随时间自然下降,因此结论可能并非美沙酮和丁丙诺啡两者均降低渴求。
  • 作者认为由于丁丙诺啡优于美沙酮,只有丁丙诺啡确实降低渴求。

研究设计与样本

  • 随机临床试验,样本为40名符合DSM-5甲基苯丙胺依赖及戒断标准、寻求治疗的男性患者。
  • 患者随机分为两组,分别接受每日40mg美沙酮或8mg丁丙诺啡,在精神科住院医院治疗17天。
  • 纳入条件包括每日使用甲基苯丙胺至少6个月,且在开始方案前刚停止使用。

主要发现

  • 全部40名患者完成研究。
  • 两种药物在甲基苯丙胺戒断期间均能有效降低渴求。
  • 丁丙诺啡组的渴求降低程度显著大于美沙酮组(P<0.05)。

关键数值与推荐

  • 主要结局包括甲基苯丙胺渴求评分、研究期间尿液药物筛查阴性(薄层色谱法)及治疗保留率。

局限性

  • 作者指出渴求预期会随时间自然下降而无任何药物,因此结论可能并非美沙酮和丁丙诺啡两者均降低渴求。
  • 作者认为由于丁丙诺啡优于美沙酮,只有丁丙诺啡确实降低渴求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We sought to test the effectiveness of methadone and buprenorphine in the treatment of methamphetamine withdrawal craving over a 17-day treatment period. METHODS: Patients were randomized into one of two groups. The study sample comprised 40 male subjects dependent on methamphetamine who met criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, for methamphetamine dependence and withdrawal and were seeking treatment. Furthermore, they should have a history of daily methamphetamine use for at least 6 months and should have discontinued their use just before starting the protocol. Patients received 40 mg of methadone or 8 mg of buprenorphine per day and were treated in an inpatient psychiatric hospital. We used methamphetamine craving score, negative urine drug screening test (thin-layer chromatography) during the study, and retention in treatment. RESULTS: All 40 patients completed the study. Both drugs were effective in decreasing methamphetamine craving during methamphetamine withdrawal. Reduction of craving in the buprenorphine group was significantly more than in the methadone group (P < 0.05). CONCLUSIONS: The results favor the efficacy and safety of buprenorphine as a short-term treatment for methamphetamine withdrawal craving. We should mention that it is to be expected that craving declines over time without any medication. Therefore, the conclusion may not be that methadone and buprenorphine both reduce the craving. Because buprenorphine is superior to methadone, only buprenorphine surely reduces craving. TRIAL REGISTRATION: Iranian Registry of Clinical Trials identifier: IRCT2015112125160N1 . Registered on 4 June 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ahmadi J, Razeghian Jahromi L. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial. Trials. 2017. PMID: 28587620. doi:10.1186/s13063-017-2007-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。